Laboratory of molecular immunology
Molecular Immunology Laboratory at the Moscow River.
Radioactive (90Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer (2018-11-30)
We report combined therapy using upconversion nanoparticles (UCNP) coupled to two therapeutic agents: beta-emitting radionuclide yttrium-90 (90Y) fractionally substituting yttrium in UCNP, and a fragment of the exotoxin A derived from Pseudomonas aeruginosa genetically fused with a targeting designed ankyrin repeat protein (DARPin) specific to HER2 receptors. The resultant hybrid complex UCNP-R-T was tested using human breast adenocarcinoma cells SK-BR-3 overexpressing HER2 receptors and immunodeficient mice, bearing HER2-positive xenograft tumors. The photophysical properties of UCNPs enabled background-free imaging of the UCNP-R-T distribution in cells and animals. Specific binding and uptake of UCNP complexes in SK-BR-3 cells was observed,with separate 90Y- and PE40-induced cytotoxic effects characterized by IC50 140 μg/mL (UCNP-R) and 5.2 μg/mL (UCNP-T), respectively. When both therapeutic agents were combined into UCNP-R-T, the synergetic effect increased markedly, ∼2200-fold, resulting in IC50 = 0.0024 μg/mL. The combined therapy with UCNP-R-T was demonstrated in vivo. PNAS USA, 2018. In colaboration with Lobachevsky University.
- (2018). Disassembling a cancer puzzle: Cell junctions and plasma membrane as targets for anticancer therapy. J Control Release 286, 125–136
- (2018). Radioactive (90Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer. Proc Natl Acad Sci U S A 115 (39), 9690–9695
- (2018). 3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development. Drug Discov Today ,
- (2018). Versatile Platform for Nanoparticle Surface Bioengineering Based on SiO2-Binding Peptide and Proteinaceous Barnase, Barstar Interface. ACS Appl Mater Interfaces 10 (20), 17437–17447
Plasmonic gold nanoparticles for photothermal therapy of cancer (2017-11-27)
The new agents for tumor theranostics with different mechanisms of action were constructed on the base of hybrid nanoparticles. The 5 nm gold nanoparticles conjugated with designed ankyrin repeat protein (DARPin), which speciﬁcally targets human epidermal growth factor receptor 2 (HER 2), are of the utmost interest. The high stability under physiological conditions and high a ﬃnity to the receptors overexpressed by cancer cells make conjugates of plasmonic gold nanostructures with DARPin molecules promising candidates for cancer photothermal therapy. This work was supported by the Russian Science Foundation (project no.14-2400106).
- (2017). Synthesis, Characterization, and Selective Delivery of DARPin-Gold Nanoparticle Conjugates to Cancer Cells. Bioconjug Chem 28 (10), 2569–2574
- (2017). Ultraviolet phototoxicity of upconversion nanoparticles illuminated with near-infrared light. Nanoscale 9 (39), 14921–14928
- (2017). Targeting group i p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene 36 (38), 5421–5431
- (2017). HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis. Oncotarget 8 (13), 22048–22058
- (2017). Deep-penetrating photodynamic therapy with KillerRed mediated by upconversion nanoparticles. Acta Biomater 51, 461–470